MTOR and Hepatic fibrosis: The NCS results of these screened compounds across 26 cell types revealed that six compounds, namely Betamethasone (a Glucocorticoid receptor agonist), VX-745 (a p38 MAPK inhibitor), Romidepsin (an HDAC inhibitor), CGK-733 (an ATM/ATR kinase inhibitor), NU-7026 (a DNA inhibitor/MTOR/PI3K inhibitor) and Lenalidomide (an antineoplastic agent), exhibited therapeutic potential for the treatment of liver fibrosis and HCC (Figure 9A).